IgA Nephropathy Market Size was Valued at USD 1.5 Billion in 2025, Set for Strong Growth Through 2036

According to DelveInsight's analysis, the IgA Nephropathy (IgAN) market size was found to be approximately ~USD 1.5 billion in the leading markets (the United States, EU4 [Germany, France, Italy, and Spain], the United Kingdom, and Japan) in 2025, and is projected to reach approximately USD 11.6 billion by 2036, growing at a CAGR of 18.6% during 2026–2036. DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the IgAN landscape.

IgAN reported approximately 135,000 diagnosed prevalent cases in the US. Improved diagnostic practices, greater disease awareness, and wider use of kidney biopsies are expected to drive the growing prevalence of IgAN. There is no cure for IgAN, and treatment focuses on reducing proteinuria, controlling blood pressure, and slowing disease progression; standard therapies include ACEis, ARBs, and SGLT2 inhibitors, while newer approaches target underlying disease mechanisms, offering precision, disease-modifying strategies that go beyond supportive care.

The IgAN-approved drugs include iptacopan (FABHALTA), atrasentan (VANRAFIA), budesonide (TARPEYO/KINPEYGO), sparsentan (FILSPARI), and sibeprenlimab (VOYXACT). Among these, VOYXACT has recently received US FDA approval, providing a first-in-class APRIL-blocking therapy that offers a novel, disease-modifying option to reduce proteinuria and slow disease progression. The IgAN pipeline includes several late-stage therapies targeting key disease mechanisms, including BAFF/APRIL dual inhibitors (povetacicept, atacicept), anti-CD38 antibodies (felzartamab, mezagitamab), complement inhibitors (ravulizumab, ARO-C3), anti-APRIL therapy (zigakibart), and the gene-silencing agent sefaxersen.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The total number of diagnosed prevalent cases of IgAN in the 7MM was approximately ~415,000 in 2025. In 2025, IgAN diagnoses across Spain showed a gender disparity, with 67% of cases occurring in males and 33% in females; Germany emerged as the leading contributor to the regional disease burden, recording the highest number of diagnosed cases in both sexes among the EU4 and the UK. The 18–45 years age group accounted for the highest number of IgAN cases in Japan, with nearly 70,000 diagnosed cases, a figure projected to rise due to improved diagnostic recognition and evolving demographic trends. In 2025, individuals aged 18–45 years accounted for the largest share of diagnosed IgAN cases in EU4 and the UK, comprising 41% of the total across all age groups, followed by the 46–65 years cohort, while the <18 years age group represented the smallest proportion of the overall case burden.

DelveInsight's report, "IgA Nephropathy Market Insights, Epidemiology and Market Forecast – 2036," provides a comprehensive analysis of the IgAN landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines IgAN market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the IgA Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here — IgA Nephropathy Market Forecast

Key Facts of the IgA Nephropathy Market Report

• Key IgAN Companies: Travere Therapeutics, Novartis, Asahi Kasei/Calliditas Therapeutics, Biogen, AstraZeneca (Alexion Pharmaceuticals), Otsuka Pharmaceutical/PANTHERx Rare, Vertex Pharmaceuticals, Takeda Pharmaceutical, and more
• Key IgAN Therapies: Iptacopan (FABHALTA), Sibeprenlimab (VOYXACT), Povetacicept (ALPN-303), Ravulizumab (ULTOMIRIS), ARO-C3, Atrasentan (VANRAFIA), Budesonide (TARPEYO/KINPEYGO), Sparsentan (FILSPARI), Zigakibart (FUB523), Felzartamab (MOR202), Atacicept, Mezagitamab (TAK-079), Sefaxersen, and more
• The IgAN market is expected to grow due to rising diagnosed and treated patient populations, earlier detection through routine urine screening, wider adoption of renal biopsy, and enhanced disease awareness during the forecast period. Furthermore, the launch of multiple first-in-class, mechanism-based therapies will significantly influence the IgAN market dynamics.

IgA Nephropathy Overview

IgAN, also known as Berger disease, is an autoimmune disease that attacks the kidneys and affects blood filtration in the kidneys' small blood vessels. IgAN occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys. It is estimated that 20–40% of people with IgAN will develop end-stage kidney disease (ESKD), requiring dialysis or kidney transplantation to survive. IgAN is more prevalent in men than in women; in most studies, except for Japan and Brazil, IgAN was over-represented in male patients compared with female patients.

Diagnosis relies entirely on histopathologic evaluation of a renal biopsy, demonstrating mesangial hypercellularity and predominant or co-dominant glomerular deposition of IgA, usually with complement C3 and variable amounts of IgG and/or IgM. Advancements in targeted therapies have broadened the treatment landscape: sparsentan (a dual endothelin and angiotensin receptor antagonist) and targeted-release budesonide offer non-immunosuppressive options for residual proteinuria, while SGLT2 inhibitors have demonstrated renal benefits in IgAN subgroups. Immunosuppressants such as rituximab and calcineurin inhibitors have shown limited benefit, and tonsillectomy remains a regionally applied adjunct in Japan.

Request the sample page for the IgA Nephropathy Market Report: https://www.delveinsight.com/report-store/iga-nephropathy-igan-market

Key Trends in IgA Nephropathy Therapeutics Market

• Shift Toward Disease-Modifying Therapies: Newer approaches target underlying disease mechanisms, offering precision strategies that go beyond supportive care to improve long-term renal outcomes.
• Expanding APRIL/BAFF-Targeted Pipeline: BAFF/APRIL dual inhibitors such as povetacicept and atacicept are advancing through late-stage development to suppress pathogenic IgA production.
• Growing Complement Inhibition Class: Complement inhibitors including ravulizumab and ARO-C3 are broadening the therapeutic landscape alongside anti-CD38 antibodies like felzartamab and mezagitamab.
• Improved Diagnostic Recognition: Broader use of renal biopsy and routine urine screening is enabling earlier diagnosis and expanding the addressable treatment pool.
• First-in-Class Approvals Reshaping Standard of Care: Recent approvals, led by VOYXACT, signal a transition from conventional supportive care toward targeted, mechanism-based therapy.
• Payer and Reimbursement Evolution: Long-term market growth will depend on payer recognition of clinical value, with reimbursement decisions increasingly tied to demonstrated reduction in proteinuria and delayed progression to ESKD.

IgA Nephropathy Epidemiology

Key findings from IgAN epidemiological analysis and forecast highlight the disease's prevalence, incidence, and patient demographics across the 7MM, including age- and gender-specific segmentation, helping stakeholders understand the scope of the disease and plan targeted interventions, research, and treatment strategies.

IgA Nephropathy Epidemiology Segmentation

The IgAN market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM, segmented into:

• Total Diagnosed Prevalent Cases of IgAN
• Gender-specific Diagnosed Prevalent Cases of IgAN
• Age-specific Diagnosed Prevalent Cases of IgAN

Download the report to understand which factors are driving IgA Nephropathy epidemiology trends @ IgA Nephropathy Epidemiology Forecast

Recent Developments in the IgA Nephropathy Treatment Landscape

• In November 2025: VOYXACT (sibeprenlimab), an APRIL-blocking IgG2 monoclonal antibody from Otsuka Pharmaceutical, received FDA approval under accelerated approval to reduce proteinuria in adults with primary IgAN; PANTHERxRare Pharmacy was selected as its exclusive specialty pharmacy.
• In ASN Kidney Week 2025: Vera Therapeutics reported positive Phase III ORIGIN atacicept data in IgAN, subsequently published in the New England Journal of Medicine.
• In June 2025: 100-week Phase I/II data for zigakibart, presented at the ERA Congress, showed sustained proteinuria remission, stable kidney function, and a favorable safety profile in patients with IgAN, supporting its continued clinical advancement.
• In September 2024: FILSPARI (sparsentan) received full FDA approval, followed by EU approval in April 2025; the drug carries boxed warnings for hepatotoxicity and teratogenicity requiring REMS monitoring.
• In August 2024: FABHALTA (iptacopan), a Complement Factor B inhibitor from Novartis, received FDA approval as an oral option for complement-mediated IgAN, though REMS is required due to infection risk.
• In July 2024: Calliditas Therapeutics reported that its partner, Viatris Pharmaceutical, initiated a Phase III clinical trial in Japan for NEFECON (marketed locally as VR-205) in Japanese patients with IgAN, with readout expected in 2026.
• Renalys Pharma reported positive topline Phase III results for sparsentan in Japanese patients with IgAN, supporting advancement toward regulatory submission in Japan.
• Takeda reported new data showing mezagitamab (TAK-079) achieved sustained preservation of kidney function through 18 months in patients with primary IgAN.

IgA Nephropathy Drugs Uptake and Pipeline Development Activities

This section focuses on the uptake rate of potential IgAN drugs expected to be launched during the forecast period (2026–2036), covering drug uptake, performance at peak, factors affecting performance during prime growth years, patient uptake by therapy, and anticipated sales generated by each drug. Povetacicept (Vertex Pharmaceuticals) and atacicept (Vera Therapeutics) neutralize BAFF and APRIL to suppress B-cell activity, while felzartamab (Biogen) and mezagitamab (Takeda) target CD38-positive plasma cells to reduce pathogenic IgA production. Other approaches include zigakibart (Novartis) targeting APRIL signaling, sefaxersen suppressing hepatic IgA synthesis via RNA interference, and complement inhibitors such as ARO-C3 and ULTOMIRIS (ravulizumab, AstraZeneca).

IgA Nephropathy Approved and Emerging Therapies

• Budesonide (TARPEYO/KINPEYGO): Asahi Kasei / Calliditas Therapeutics. Approved in the US, EU, and UK.
• Sparsentan (FILSPARI): Travere Therapeutics. Approved in the US, EU, and UK.
• Iptacopan (FABHALTA): Novartis. Approved in the US in August 2024.
• Sibeprenlimab (VOYXACT): Otsuka Pharmaceutical. Approved in the US in November 2025 under accelerated approval.
• Atrasentan (VANRAFIA): Developed by Novartis. Approved.
• Zigakibart (FUB523, formerly BION-1301): Novartis. In Phase III, with regulatory submission planned for 2027.
• Povetacicept (ALPN-303): Vertex Pharmaceuticals. Currently in Phase III development.
• Felzartamab (MOR202): Biogen. In Phase III, with a US launch anticipated in 2028.
• Atacicept: Vera Therapeutics. Currently in Phase III development.
• Mezagitamab (TAK-079): Takeda Pharmaceutical. In late-stage development.
• Sefaxersen (RG6299; IONIS-FB-LRx): In late-stage development.
• Ravulizumab (ULTOMIRIS): AstraZeneca / Alexion Pharmaceuticals. In late-stage development.
• ARO-C3: Arrowhead Pharmaceuticals. In late-stage development.

In 2025, the total IgAN market size across the US was estimated at USD 1.2 billion, the largest among the 7MM. Driven by a projected CAGR of 16.1% during 2026–2036, the US market is anticipated to reach USD 8.1 billion by 2036. By 2036, among all IgAN therapies, the highest revenue in the 7MM is estimated to be generated by ALPN-303 (Povetacicept).

To know more about IgAN companies working in the treatment market, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment

IgA Nephropathy Market Drivers

• Increasing diagnosed and treated patient population across the 7MM, supported by earlier detection through routine urine screening
• Wider adoption of renal biopsy enabling more definitive and earlier diagnosis
• Improved disease recognition among nephrologists and enhanced disease awareness
• Emergence of next-generation, mechanism-based pipeline therapies broadening the therapeutic landscape
• Growing focus on slowing progression to end-stage kidney disease, supporting long-term treatment demand
• Recent first-in-class approvals, led by VOYXACT, signaling commercial momentum across the APRIL/BAFF and complement-inhibition classes

IgA Nephropathy Market Barriers

• Delayed and complex diagnosis of IgAN, relying entirely on histopathologic evaluation of renal biopsy
• Inadequate long-term solutions for high-risk groups, with 20–40% of patients progressing to end-stage kidney disease
• Need for safer therapeutic alternatives with improved tolerability, given REMS requirements and boxed warnings on several approved therapies
• Integrated management of comorbidities in IgAN patients
• Heterogeneity in IgAN phenotypes and variable disease progression, complicating patient stratification and delaying initiation of optimal targeted treatments
• Long-term market growth dependent on payer recognition of clinical value and demonstrated real-world safety outcomes

Scope of the IgA Nephropathy Market Report

• Study Period: 2022–2036
• Forecast Period: 2026–2036
• Coverage: Global
• Key IgAN Companies: Travere Therapeutics, Novartis, Asahi Kasei/Calliditas Therapeutics, Biogen, AstraZeneca (Alexion Pharmaceuticals), Otsuka Pharmaceutical/PANTHERx Rare, Vertex Pharmaceuticals, Takeda Pharmaceutical, and more
• Key IgAN Therapies: Iptacopan (FABHALTA), Sibeprenlimab (VOYXACT), Povetacicept (ALPN-303), Ravulizumab (ULTOMIRIS), ARO-C3, and more
• IgAN Market Segmented By: Region/geographies, drugs/therapies
• Analysis Covered: Addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, attribute analysis, unmet need

Discover more about therapies set to grab major IgA Nephropathy market share @ IgA Nephropathy Treatment Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.